Changeflow GovPing Pharma & Healthcare Montelukast Phase 2 Trial for Acute Myocardial ...
Routine Notice Added Final

Montelukast Phase 2 Trial for Acute Myocardial Infarction

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered a Phase 2 randomized controlled trial (NCT07537868) evaluating Montelukast 10 mg oral tablets for acute myocardial infarction. The trial, sponsored by Mansoura University (Egypt), will enroll participants randomized to Montelukast or placebo to assess anti-inflammatory and cardioprotective effects via inflammatory markers and cardiac injury indicators. The study has an estimated start date of April 17, 2026.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This notice registers a new Phase 2 clinical trial on ClinicalTrials.gov (NCT07537868) to evaluate Montelukast in acute myocardial infarction patients. The randomized, placebo-controlled study will assess whether Montelukast 10 mg influences inflammatory markers and reduces cardiac injury following heart attack.

Affected parties including trial sponsors, clinical investigators, and pharmaceutical companies should note this trial registration for competitive landscape awareness and patient referral considerations. The trial does not create compliance obligations for third parties; it is an informational record of an ongoing research study.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction

Phase 2 NCT07537868 Kind: PHASE2 Apr 17, 2026

Abstract

This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University

Conditions: Acute Myocardial Infarction (AMI)

Interventions: Montelukast 10 Mg Oral Tablet, placebo

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07537868

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Drug research Cardiac care
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!